![The F-35’s future: Can the fifth-gen fighter withstand political, technological headwinds? [Video]](https://breakingdefense.com/wp-content/uploads/sites/3/2024/04/240401_f35_clouds_8270083-scaled-e1711999276822.jpg?#)
Cullinan pens $700M pact for BCMA bispecific to pair with another autoimmune T-cell engager
Cullinan Therapeutics is paying $20 million upfront for a BCMAxCD3 bispecific T-cell engager that the biotech plans to pair with its existing CD19 candidate
Cullinan Therapeutics is paying $20 million upfront for a BCMAxCD3 bispecific T-cell engager that the biotech plans to pair with its existing CD19 candidate
